CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma

Dok Hyun Yoon, Young Wha Koh, Hyo Jeong Kang, Shin Kim, Chan Sik Park, Sang wook Lee, Cheolwon Suh, Jooryung Huh

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Background: Limited progress had been made in prognostic stratification of patients with Hodgkin lymphoma (HL) until recent studies suggested that the number of CD68-expressing macrophages is prognostic in classical HL. However, its significance in Asian patients with HL has not been explored yet perhaps because of its low incidence in Asia. Methods: In this work, we performed immunohistochemical analysis of CD163, as well as CD68, in 144 Korean patients with HL treated between November 1990 and December 2009 in a single center. The relative percentages of CD68+ and CD163+ cells with respect to the overall cellularity (CD68 index and CD163 index, respectively) were correlated with clinical outcomes. Results: Both high CD68 and CD163 indices (>20%) were associated with a rise in treatment-related deaths and poorer event-free survival (P=0.009 and P=0.0023, respectively), disease-specific survival (P=0.011 and P=0.001), and overall survival (P=0.023 and P=0.001). In particular, a high CD163 index was related to lower complete response (CR) rate (P=0.022) and shorter duration of CR (P=0.030). Conclusions: High index of either CD68 or CD163 (>20%) is significantly correlated with poor prognosis in Korean patients with HL. CD163, a specific marker of macrophages, seems to be another prognostic factor for classical HL.

Original languageEnglish (US)
Pages (from-to)292-305
Number of pages14
JournalEuropean Journal of Haematology
Issue number4
StatePublished - Apr 2012


  • CD163
  • CD68
  • Hodgkin lymphoma
  • Macrophage


Dive into the research topics of 'CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this